Castelgrande Lectures

New cancer therapies. A conference with Prof. Douglas Hanahan



Castelgrande Hall Salita al Castelgrande Bellinzona Monday 15 April, 2019 5 pm



Università della Svizzera italiana

Institute of Oncology Research



IOR An institute affiliated to USI

More information info@ior.usi.ch

Castelgrande Lectures New cancer therapies. A conference with Prof. Douglas Hanahan



Douglas Hanahan
Professor at the Swiss
Federal Institute
of Technology of
Lausanne and
Director of the Swiss
Institute for
Experimental Cancer
Research (ISREC)

Douglas Hanahan, Professor at the Swiss Federal Institute of Technology of Lausanne and Director of the Swiss Institute for Experimental Cancer Research (ISREC), will be the guest of the first Castelgrande Lecture. The annual conferences are promoted by the Institute of Oncology Research (IOR, affiliated to USI) with the aim of strengthening connections between Ticino, local institutions, and the scientific community, while promoting love for science and emphasising its importance for quality healthcare, and the region's economic development.

During his lecture open to the public and held in English, Prof. Hanahan will discuss the challenges that future generations of scientists, doctors, politicians, and the community will have to face in order to defeat the disease in the next few decades.

Prof. Hanahan's research led to the discovery of a process named angiogenic switch which supports the growth of the tumour through the production of new blood vessels. His work has also inspired the clinical development of therapies that can halt the disease. Prof. Hanahan is internationally recognised as an excellent scientific disseminator and promoter of biomedical research. Thanks to his contribution, the role of the ISREC of Lausanne has significantly strengthen worldwide in the field of oncology research, and is now setting an example in Switzerland.

The lecture "Hallmarks of Cancer: Thinking globally about new cancer therapies" will launch the Castelgrande Lectures, that will feature every year a leading scientist in biomedical sciences, and in particular in the field of oncology.



